Document is current
Any future updates will be listed below
-
Authors
Knox, Jessica https://orcid.org/0000-0003-1465-5852
Burns, Andrew R. https://orcid.org/0000-0002-8966-1280
Cooke, Brittany
Cammalleri, Savina R.
Kitner, Megan
Ching, Justin https://orcid.org/0000-0002-2511-216X
Castelli, Jack M. P.
Puumala, Emily
Snider, Jamie https://orcid.org/0000-0001-5647-3729
Koury, Emily https://orcid.org/0000-0001-7869-504X
Collins, J. B. https://orcid.org/0000-0003-0808-5216
Geissah, Salma
Dowling, James J. https://orcid.org/0000-0002-3984-4169
Andersen, Erik C.
Stagljar, Igor https://orcid.org/0000-0002-5260-3327
Cowen, Leah E. https://orcid.org/0000-0001-5797-0110
Lautens, Mark https://orcid.org/0000-0002-0179-2914
Zasada, Inga
Roy, Peter J. https://orcid.org/0000-0003-2959-2276
-
Funding
Funding for this research was provided by:
Canada Research Chairs
- License Information
-
More Information
Article History
Received: 25 October 2023
Accepted: 18 June 2024
First Online: 2 July 2024
Competing interests
: L.E.C. is co-founder and shareholder in Bright Angel Therapeutics, a platform company for development of novel antifungal therapeutics, and is a Science Advisor for Kapoose Creek, a company that harnesses the therapeutic potential of fungi. Mention of trade names or commercial products in this publication is solely for the purpose of providing specific information and does not imply recommendation or endorsement by the U.S. Department of Agriculture. USDA is an equal opportunity provider and employer. J.K., A.R.B., B.C., and P.J.R. have a patent application related to the Cyprocides. The remaining authors declare no competing interests.
